Catalytic synthesis process of sitagliptin phosphate by cyclodiene method
Patent Information
- Application Number
- CN202610291998.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-11
- Publication Date
- 2026-07-03
AI Technical Summary
Existing processes for synthesizing sitagliptin suffer from problems such as expensive and difficult-to-recover catalysts, high reaction safety risks, low yields, and difficulty in industrialization. Furthermore, enzyme structures in enzyme-catalyzed processes are unstable and difficult to recycle.
An immobilized enzyme cyclic catalytic system was adopted. By immobilizing the enzyme-carrying column and optimizing the reaction conditions, transaminase (ATA-117) was immobilized with epoxy resin HFA001 and cyclic catalytic reaction was carried out at 45℃ and pH 9.5-10.0. The diketone substrate was synthesized by combining a one-pot cooking method, and sitagliptin phosphate was obtained by subsequent precise purification process.
It significantly improves the safety and yield of synthesis, reduces production costs, achieves efficient recycling of enzymes, has strong process stability, is suitable for industrial-scale production, and meets the requirements of green chemistry.
Smart Images

Figure CN122326693A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of sitagliptin phosphate preparation technology, specifically to a cyclic enzymatic catalytic synthesis process for sitagliptin phosphate. Background Technology
[0002] Sitagliptin, as an important dipeptidyl peptidase-IV (DPP-IV) inhibitor, has significant application value in the treatment of type II diabetes. It can not only effectively lower blood sugar and improve insulin resistance, but also has outstanding advantages such as high safety and low incidence of adverse reactions such as hypoglycemia and weight gain. It can be used alone or in combination with other oral hypoglycemic agents, and has broad prospects for clinical application.
[0003] However, the synthesis process of sitagliptin has long faced numerous technical bottlenecks. Currently, the mainstream synthesis method in the industry is catalytic hydrogenation (…). Figure 9 ) and chemical reduction method ( Figure 10 The aforementioned processes all require the prior synthesis of specific sitagliptin catalytic precursors, followed by hydrogenation and reduction reactions using expensive catalysts or reducing agents to generate the target product. However, such chemical synthesis routes have inherent drawbacks: on the one hand, the catalysts used in the catalytic reduction process are expensive and difficult to recycle after the reaction, resulting in high synthesis costs; on the other hand, the hydrogenation reaction itself carries high safety risks, requires stringent operating conditions, and is limited by reaction thermodynamics and kinetics, resulting in low synthesis yields, which severely restricts the large-scale production and widespread application of sitagliptin.
[0004] To overcome the drawbacks of chemical synthesis processes, Merck & Co., Inc. collaborated with Codexis Biotechnology to develop an enzyme-catalyzed biosynthetic technology for the synthesis of sitagliptin. Figure 11 This method achieves efficient synthesis of sitagliptin through transaminase-catalyzed reaction of diketone precursor substrates, theoretically overcoming the limitations of traditional chemical synthesis. However, in practical industrial applications, this enzyme-catalyzed method still suffers from key technical defects: as a bioactive enzyme, the catalytic structure of transaminase is easily affected by reaction conditions such as chemical solvents and catalytic pressure, resulting in physical deformation or even irreversible damage, leading to decreased enzyme catalytic activity and insufficient reaction stability; at the same time, free transaminase is difficult to recycle and needs to be frequently replenished through fermentation, which not only increases the complexity of the production process but also further increases production costs, limiting the industrial-scale promotion of this technology.
[0005] Therefore, developing a sitagliptin synthesis process that boasts high yield, strong safety, low production cost, and stable industrial-scale production capability has become a pressing technical challenge in this field. Addressing the shortcomings of existing chemical synthesis processes—high risk, high cost, and low yield—and the poor enzyme structural stability and difficulty in recycling in existing enzyme-catalyzed processes, there is an urgent need to construct a new sitagliptin synthesis route that combines high efficiency, stability, and economy through process innovation and technological optimization. This will meet the large-scale clinical drug demand and advance the synthesis technology of diabetes treatment drugs. Summary of the Invention
[0006] The purpose of this invention is to address the shortcomings of existing technologies by providing a cyclic enzymatic catalytic synthesis process for sitagliptin phosphate, thereby solving the problems mentioned in the background section.
[0007] To achieve the above objectives, the present invention provides the following technical solution: a cyclic enzymatic catalytic synthesis process for sitagliptin phosphate, using diketone substrates as reactants, and employing an immobilized enzyme cyclic catalytic system to replace the traditional hydrogenation chemical synthesis process. The immobilized enzyme cyclic catalytic system includes an immobilized enzyme column and optimized reaction conditions. The specific steps are as follows: Step (1): Synthesis of the diketone substrate: Starting with 2,2-dimethyl-1,3-dioxane-4,6-dione and 2,3,5-trifluorophenylacetic acid, the product was reacted in acetonitrile in the presence of N,N-diisopropylethylamine and a catalytic amount of 4-dimethylaminopyridine to generate the Meldrum addition product. The product was then reacted with triazole piperazine hydrochloride in a one-pot reaction system regulated by trifluoroacetic acid to synthesize the diketone substrate. Step (2): Preparation of immobilized enzyme column: The transaminase (ATA-117) prepared by fermentation was subjected to cell wall disruption, impurity removal, and ultrafiltration concentration to obtain enzyme concentrate. The concentrate was then immobilized by stirring with epoxy resin HFA001 at 30-40℃ for 12 hours, controlling the immobilization of 0.6U enzyme activity per 1g of epoxy resin. After filtration and washing, the concentrate was packed into a chromatography column with a height-to-diameter ratio of 4:3. The volume of the immobilized enzyme packing was two-thirds of the column volume. The concentrate was then stored after being immersed in distilled water below 8℃ for later use. Step (3): Cyclic catalytic reaction: The diketone substrate is dissolved in dimethyl sulfoxide to form a substrate solution, which is then mixed with a catalytic solution containing pyridoxal phosphate and 3M isopropylamine hydrochloride. Cyclic catalysis is carried out in a fixed enzyme-carrying column. The reaction temperature is controlled at 45℃, the pH value is 9.5-10.0, the substrate solution flow rate is 4.5-5.0 L / h, the circulation liquid flow rate is 600-800 L / h, and the reaction is carried out for 10 hours until the substrate is completely converted. Step (4): Product separation and purification: The catalyst solution and the eluent are combined, and the product is purified by acid extraction, alkali extraction, organic phase washing and drying, vacuum concentration, crystallization and low temperature vacuum drying to obtain sitagliptin base.
[0008] As a preferred technical solution of the present invention, the specific conditions for the "one-pot" reaction in step (1) are as follows: react at 55°C for 6 hours, add triazole piperazine hydrochloride first, then add trifluoroacetic acid dropwise, continue to keep warm after the addition is completed, add 5% NaHCO3 aqueous solution dropwise twice after the reaction is completed, cool to 0-5°C and stir to crystallize, and obtain the diketone substrate by washing and drying.
[0009] As a preferred technical solution of the present invention, the fermentation preparation process of transaminase (ATA-117) in step (2) includes engineered bacteria culture, cell wall disruption, impurity removal and ultrafiltration concentration, wherein the enzyme activity of the enzyme concentrate after ultrafiltration concentration is not less than 8.3 g / L.
[0010] As a preferred technical solution of the present invention, the composition of the catalyst solution in step (3) is: 60g of pyridoxal phosphate, 1.5L of 3M isopropylamine hydrochloride (pH9.5), 40L of dimethyl sulfoxide, and 30L of water. The concentration of the substrate solution is 4kg of diketone substrate dissolved in 16L of dimethyl sulfoxide.
[0011] As a preferred technical solution of the present invention, the cyclic catalytic process of the immobilized enzyme column in step (3) includes washing, catalytic solution circulation, substrate addition catalysis, top washing catalytic solution, elution, top washing eluent and storage steps. The immobilized enzyme column can continuously cyclically catalyze more than 10 batches, and the substrate conversion rate of each batch is not less than 95%.
[0012] As a preferred technical solution of the present invention, the specific conditions for separation and purification in step (4) are as follows: (a) Acidification treatment: Adjust the pH of the combined solution to 2.0-3.0 with hydrochloric acid, add 5% sodium chloride, stir at 50°C for 30 min, and then cool to 10-30°C; (b) Acid extraction: Extract twice with 1 / 4 volume of ethyl acetate, and collect the aqueous phase; (c) Alkali-adjusted extraction: Adjust the pH of the aqueous phase to 11.0 with 12.0M NaOH, and extract three times with 1 / 3 volume of ethyl acetate, readjusting the pH to 11.0 before each extraction; (d) Organic phase treatment: washed with saturated NaCl solution, dried with anhydrous sodium sulfate, and filtered through a 0.45 μm organic filter membrane; (e) Vacuum concentration: Concentrate at 40±5℃ and a vacuum of -0.10 to -0.06 MPa until no liquid flows out; (f) Crystallization: Add isopropanol and heat to 55-65℃ to dissolve, add n-heptane dropwise, cool to 15-20℃ and stir to crystallize; (g) Drying: 40±5℃, vacuum degree -0.10~-0.06MPa, drying tray thickness <2.0cm, and collect the material after the drying loss is qualified.
[0013] As a preferred technical solution of the present invention, the preparation method of the immobilized enzyme packing is as follows: the transaminase concentrate and epoxy resin HFA001 are stirred and reacted at 30-40℃ for 12 hours, the excess enzyme solution is removed by filtration, and the mixture is washed with pure water until there is no obvious foam. The immobilized enzyme packing is stored in purified water at 4-8℃, and the enzyme activity stability is maintained for more than 10 batches of catalytic cycles without decay.
[0014] Compared with the prior art, the beneficial effects of the present invention are: 1. Significantly improves synthesis safety and reduces production risks. This invention completely replaces the traditional hydrogenation chemical synthesis process with an immobilized enzyme cyclic catalysis process, avoiding the technical defects of high pressure and high risk in the hydrogenation reaction process. At the same time, it avoids the use of expensive and difficult-to-recover chemical catalysts, eliminating the safety hazards caused by chemical reduction reactions from the essence of the process, simplifying the safety management process of production operations, and providing a more reliable safety guarantee for large-scale industrial production.
[0015] 2. Significantly improves synthesis yield and product purity, ensuring product quality. By specifically screening transaminase (ATA-117) and optimizing reaction conditions (temperature 45℃, pH 9.5-10.0, etc.), combined with the stabilizing effect of the immobilized enzyme column on the enzyme structure, this invention effectively solves the technical pain point of enzyme structure deformation and destruction due to solvent and pressure in traditional enzyme catalysis processes. Industrial-scale experiments have verified that the yield of this invention remains stable at 80%-85% after more than 10 consecutive batches of cyclic catalysis, with a substrate conversion rate of no less than 95% per batch. Furthermore, through precise purification processes (acidification extraction, alkali-adjusted extraction, stepwise crystallization, etc.), the purity of the product is ensured to meet pharmaceutical standards, significantly outperforming the low-yield characteristics of traditional chemical synthesis processes.
[0016] 3. Achieving efficient recycling of enzymes and significantly reducing production costs: This invention innovatively uses epoxy resin HFA001 to prepare immobilized enzyme columns, which can catalyze more than 10 batches of transaminase after immobilization, with no significant decrease in enzyme activity stability. This greatly reduces the frequency and amount of transaminase fermentation preparation, thus lowering the consumption cost of biological enzyme preparations. At the same time, the "one-pot" synthesis of diketone substrates, reuse of circulating catalytic liquid, and efficient product extraction design in the process reduce reagent waste and waste liquid discharge, and lower raw material consumption and environmental treatment costs. The overall production cost is reduced by more than 30% compared with traditional processes, demonstrating strong economic viability for industrial application.
[0017] 4. The process exhibits strong stability and is easily scaled up for industrial applications. This invention clearly defines key process conditions such as the preparation parameters of the immobilized enzyme column (height-to-diameter ratio 4:3, 0.6U of enzyme activity fixed per 1g of epoxy resin), the catalytic solution ratio, reaction flow rate, and temperature and pH control range, thus forming a standardized production process. Scale-up experiments in the workshop have verified that this process can stably achieve large-scale production of 4kg of substrate, with minimal fluctuations in yield and purity across batches. The process demonstrates excellent reproducibility, overcoming the technical bottleneck of existing enzyme catalysis processes that are difficult to scale up industrially, and is suitable for large-scale production needs.
[0018] 5. Green and environmentally friendly, in line with the trend of sustainable development, the process of this invention does not require the use of precious metal catalysts and highly polluting chemical reducing agents. The reaction conditions are mild (around 45°C, near neutral pH), and the energy consumption is significantly lower than that of traditional high-temperature and high-pressure chemical synthesis processes. At the same time, the recycling of the fixed enzyme column reduces the discharge of wastewater and waste residue during the bio-enzyme fermentation process. The reagents can be efficiently recovered during the product purification process. The overall discharge of waste gas, wastewater, and solid waste is reduced by more than 50% compared with traditional processes, which is in line with the policy guidance and technological trend of green chemistry and sustainable development in the pharmaceutical industry.
[0019] In summary, this invention, through the innovative design of an immobilized enzyme cyclic catalytic system, simultaneously solves multiple technical problems in the existing sitagliptin synthesis process, such as poor safety, high cost, low yield, and difficulty in industrial scale-up. It provides a brand-new technical solution for the large-scale, low-cost, and highly safe production of sitagliptin, and has significant industrial application value and promotion prospects. Attached Figure Description
[0020] Figure 1 This is a reaction route diagram for the synthesis of sitagliptin catalyzed by cyclic transaminase according to the present invention; Figure 2 This is a diagram of the sitagliptin enzyme-carrying column catalytic reaction of the present invention; Figure 3 This is a high-performance liquid chromatogram of the sitagliptin substrate solution of the present invention; Figure 4This is a high-performance liquid chromatogram of the reaction solution after the sitagliptin substrate of the present invention has been catalyzed by an enzyme-carrying column. Figure 5 The photon nuclear magnetic resonance (NMR) spectrum of sitagliptin of the present invention in DMSO-NEW solvent at 500 MHz is shown. Figure 6 The carbon NMR spectrum of sitagliptin of the present invention in DMSO-NEW solvent at 126 MHz is shown. Figure 7 The photon nuclear magnetic resonance (NMR) spectrum of sitagliptin of the present invention in CDCl3 solvent at 400 MHz is shown. Figure 8 The carbon NMR spectrum of sitagliptin of the present invention in CDCl3 solvent at 101 MHz is shown. Figure 9 This is a synthetic route diagram for the synthesis of sitagliptin via catalytic hydrogenation in the background art of this invention; Figure 10 This is a synthetic route diagram for the chemical reduction method of sitagliptin in the background art of this invention; Figure 11 This is a synthetic route diagram for the synthesis of sitagliptin using the cyclic transaminase method in the background art of this invention. Detailed Implementation
[0021] The preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings, so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby providing a clearer and more explicit definition of the scope of protection of the present invention.
[0022] I. Experimental Preparation (a) Reagents and Instruments Reagents: 2,4,5-Trifluorophenylacetic acid (analytical grade), 2,2-dimethyl-1,3-dioxane-4,6-dione (analytical grade), 4-dimethylaminopyridine (DMAP, analytical grade), N,N-diisopropylethylamine (i-Pr2NEt, analytical grade), neopentanoyl chloride (analytical grade), triazole piperazine hydrochloride (analytical grade), trifluoroacetic acid (analytical grade), 5% NaHCO3 aqueous solution (homemade), dimethyl sulfoxide (DMSO, analytical grade), pyridoxal phosphate (PLP, analytical grade), 3M isopropylamine hydrochloride (homemade, pH 9.5), 4M isopropylamine solution (homemade), hydrochloric acid (analytical grade), 12.0M NaOH solution (homemade), ethyl acetate (analytical grade), saturated NaCl solution (homemade), anhydrous sodium sulfate (analytical grade), isopropanol (analytical grade), n-heptane (analytical grade), and all other reagents were of analytical grade.
[0023] Instruments: 2500mL three-necked flask, glass-lined reaction vessel, DN600×1500 chromatography column (Hanbang Technology), Ulimate 3000 high performance liquid chromatograph (Thermo Scientific), peristaltic pump, low temperature vacuum drying oven, fermenter, ultrafiltration equipment, constant temperature water bath, centrifuge, and vacuum distillation apparatus.
[0024] (II) Preparation of key intermediates and materials Preparation of transaminase (ATA-117) concentrate: Engineered bacteria expressing ATA-117 were cultured in a fermenter. After fermentation, the bacterial cells were collected, homogenized by a high-pressure homogenizer, and centrifuged to remove impurities to obtain crude enzyme solution. The solution was then concentrated by ultrafiltration to obtain transaminase concentrate with an enzyme activity of 8.3 g / L, which was stored at 4°C for later use.
[0025] Preparation of immobilized enzyme column: Take epoxy resin HFA001 carrier, add the above-mentioned transaminase concentrate, and stir the reaction at 30-40℃ for 12 hours. During this period, monitor enzyme activity immobilization to ensure that 0.6U of enzyme activity is immobilized per 1g of epoxy resin. After the reaction, filter to remove excess enzyme concentrate. Wash the immobilized enzyme packing material repeatedly with purified water until no obvious foam is present. Pack this packing material into a DN600×1500 chromatography column with a height-to-diameter ratio of 4:3, filling the packing material to two-thirds of the column volume. Immerse the immobilized enzyme in distilled water, adjust the column jacket water temperature to below 8℃, and seal for later use.
[0026] Example 1: Synthesis of diketone substrates, such as Figure 1 As shown: Add 150g (0.789mol) of 2,4,5-trifluorophenylacetic acid, 125g (0.868mol) of 2,2-dimethyl-1,3-dioxane-4,6-dione, 7.7g (0.063mol) of DMAP and 525mL of dimethylacetamide to a 2500mL three-necked flask, and stir until well mixed.
[0027] 296 mL (1.696 mol) of N,N-diisopropylethylamine was added at room temperature in one go. The temperature of the reaction system was raised to 55 °C. 107 mL (0.868 mol) of neopentanoyl chloride was slowly added dropwise over 1-2 hours. After the addition was completed, the reaction was continued at 55 °C for 2 hours.
[0028] After the reaction was complete, triazole piperazine hydrochloride was added all at once, followed by the slow addition of 18 mL (0.237 mol) of trifluoroacetic acid, and the reaction was carried out at 55 °C for 6 hours.
[0029] After the reaction is terminated, add 620 mL of 5% NaHCO3 aqueous solution dropwise between 20-45℃. After the addition is complete, stir at 20-30℃ for 2 hours, and then add another 520 mL of 5% NaHCO3 aqueous solution dropwise over 2-3 hours.
[0030] The reaction solution was cooled to 0-5℃, stirred for 1 hour, and then filtered. The wet filter cake was washed with 300 mL of 20% dimethylacetamide aqueous solution, followed by two washes with 400 mL of the same solution. Finally, the filter cake was washed with 400 mL of water. The filter cake was dried at ambient temperature to obtain the diketone substrate with a yield of 92.3% and a purity of 98.5% as determined by HPLC.
[0031] Example 2: Cyclic catalytic synthesis of sitagliptin using an immobilized enzyme column, as shown in the example. Figure 2 As shown, (a) Preparation of catalyst solution According to the proportions shown in Table 1, accurately weigh 60g of pyridoxal phosphate, add 1.5L of 3M isopropylamine hydrochloride (pH 9.5), 40L of DMSO and 30L of water, place in a reactor and stir until dissolved to obtain a catalyst solution.
[0032] Table 1: Catalyst solution ratio
[0033] (ii) Pretreatment of enzyme-carrying column Cleaning: Take container No. 1 and fill it with 300L of purified water. Use a peristaltic pump to inject the purified water into the fixed enzyme column until the carrier is completely submerged. Connect the lower end of the enzyme column to container No. 2. After the purified water has drained, the cleaning is complete.
[0034] Preparation of catalytic solution: The prepared catalytic solution is injected into the enzyme-carrying column through a peristaltic pump until the carrier is completely submerged. The lower end of the enzyme-carrying column is connected to the reactor. The circulation flow rate of the peristaltic pump is controlled at 600-800 L / h to circulate the catalytic solution between the reactor and the enzyme-carrying column, so as to keep the liquid level in the enzyme-carrying column constant.
[0035] (III) Cyclic catalytic reaction 4 kg of diketone substrate (h) was dissolved in 16 L of DMSO to prepare sitagliptin substrate solution, which was then placed in a mother liquor tank.
[0036] Catalysis: The temperature of the enzyme-carrying column and the reactor is controlled at 45℃ by using jacketed water. After the temperature of the catalytic solution stabilizes, the substrate solution is added to the reactor at a flow rate of 4.5-5.0 L / h and the addition is completed within 4 hours. During the process, the pH of the catalytic solution is adjusted to 9.5-10.0 with 4M isopropylamine solution.
[0037] After the addition is complete, maintain the temperature at 45°C and the circulation rate at 600-800 L / h for 10 hours to continue the reaction. Monitor the reaction progress in real time by HPLC until no substrate remains in the detection solution.
[0038] Washing the catalyst solution: After the reaction is complete, release the catalyst solution and add 50L of purified water into the enzyme-carrying column in portions to wash out about 45L of catalyst solution remaining in the column. Combine this with the previously released catalyst solution to obtain about 110-120L of catalyst solution.
[0039] (iv) Elution and preservation of enzyme-carrying columns Elution: Add 65L of purified water to the reactor and inject the enzyme-carrying column into it through a peristaltic pump until the carrier is completely submerged. Connect the lower end of the tubing to the reactor and control the circulation flow rate to 600-800L / h. Circulate and elute at 45℃ for 1 hour. During the elution process, adjust the pH to 9.5-10.0 with 4M isopropylamine. After the elution is complete, release the eluent.
[0040] Top wash eluent: Add 50L of purified water to the enzyme-carrying column in portions, and wash out about 45L of residual eluent in the column. Combine this eluent with the above eluent to obtain about 110-120L of eluent.
[0041] Washing: Wash the enzyme column again with 300L of purified water. After washing, immerse the immobilized carrier in purified water and store it at 4-8℃ for the next batch of reaction.
[0042] Example 3: Isolation and purification of sitagliptin products Acidification treatment: Place the combined catalyst solution and eluent (about 220-240L) in a glass-lined reaction vessel, adjust the pH of the solution to 2.0-3.0 with hydrochloric acid, add 12kg of 5% sodium chloride, heat to 50℃ and stir for 30min, then cool to 10-30℃.
[0043] Acidification extraction to remove impurities: Add 1 / 4 volume (about 60L) of ethyl acetate to the acidified solution, stir and extract for 10 minutes, let stand for 1-2 hours, separate the liquid and collect the aqueous phase; repeat the extraction once and combine the two aqueous phases.
[0044] Alkali-adjusted extraction: Transfer the aqueous phase to another glass-lined reaction vessel, adjust the pH to 11.0 with 12.0M NaOH solution, stir for 10 minutes, add 1 / 3 volume (about 80L) of ethyl acetate, stir and extract for 10 minutes, let stand for 30 minutes, separate the liquid and collect the organic phase; repeat the extraction twice, readjust the pH of the aqueous phase to 11.0 before each extraction, and combine the three organic phases.
[0045] Organic phase washing and drying: The combined organic phases were transferred to a glass-lined reaction vessel, saturated NaCl solution was added, stirred for 10 minutes, allowed to stand for 20 minutes, mixed for 2 minutes, and allowed to stand for another 30 minutes. The organic phases were collected by separation. 12 kg of anhydrous sodium sulfate was added to the organic phases, stirred and dried for 2 hours, and filtered through a 0.45 μm organic filter membrane. The filtrate was collected.
[0046] Vacuum concentration: Transfer the filtrate to a glass-lined reaction vessel, control the water bath temperature at 40±5℃ and the vacuum degree at -0.10~-0.06MPa, concentrate until no liquid flows out, and record the temperature and vacuum degree every 2 hours.
[0047] Crystallization: After concentration, add 6 kg of isopropylamine, control the temperature of the liquid at 55-65℃ and stir until clear. Slowly add 18 kg of n-heptane over 1-2 hours. After the addition is complete, control the temperature of the liquid to 15-20℃ over 2-3 hours. Stir for 1 hour and then centrifuge and filter. Wash the filter cake with isopropanol-n-heptane (0.8 kg-3.2 kg) solution and centrifuge and filter again until no liquid flows out.
[0048] Drying: The wet filter cake was spread evenly on a drying tray in a low-temperature vacuum drying oven, with a thickness of <2.0 cm. The oven water bath temperature was controlled at 40±5℃ and the vacuum degree at -0.10~-0.06MPa. Drying was carried out under reduced pressure for 4 hours, recording the temperature and vacuum degree every hour and turning the cake over every 2 hours. After the drying loss was found to be within acceptable limits, 3.3 kg of sitagliptin bases were obtained, with a yield of 82.5%. The purity was 99.2% as determined by HPLC. The ¹H NMR and ¹³C NMR spectra were consistent with the target product. Figures 5-8 ; Figure 5 The image shows the 1H NMR spectrum of sitagliptin in DMSO-NEW solvent at 500 MHz. The horizontal axis represents the chemical shift δ (ppm), and the vertical axis represents the signal intensity. The spectrum clearly shows the chemical shift signals of different hydrogen atoms in the sitagliptin molecule (δ: 7.52 (s, 1H), 7.47 – 7.33 (m, 1H), 4.92 (s, 2H), 4.24 (s, 1H), 4.14 (s, 1H), 3.98 (s, 4H), 3.93 (s, 1H), 3.43 – 3.34 (m, 1H)), which can be used to confirm the chemical structure of the synthesized product and is one of the key bases for product structure identification.
[0049] Figure 6This is the carbon NMR spectrum of sitagliptin in DMSO-NEW solvent at 126 MHz; the horizontal axis represents chemical shift δ (ppm), and the vertical axis represents signal intensity. The spectrum shows the chemical shift signals of different carbon atoms in the sitagliptin molecule (δ: 201.29, 201.23, 166.79, 166.71, 151.24, 145.16, 117.81, 48.36, 48.18, 43.99, 43.49, 42.88, 42.18, 42.10, 38.87, 37.93), and... Figure 5 The 1H NMR spectrum, when used in conjunction with the 1H NMR spectrum, can comprehensively and accurately verify the chemical structure of the synthesized product, ensuring the correctness of the product.
[0050] Figure 7 The image shows the 1H NMR spectrum of sitagliptin in CDCl3 solvent at 400 MHz. The x-axis represents the chemical shift δ (ppm), and the y-axis represents the signal intensity. The chemical shift signals are: δ: 7.04 (dd, J = 17.0, 8.9 Hz, 1H), 6.86 (td, J = 9.6, 6.7 Hz, 1H), 5.12 – 4.79 (m, 2H), 4.32 – 3.84 (m, 4H), 3.52 (s, 1H), 2.88 – 2.31 (m, 4H), 1.56 (d, J = 12.1 Hz, 2H). This spectrum serves as... Figure 8 The addition of proton NMR spectroscopy further validated the chemical structure of sitagliptin in different solvent systems, improving the accuracy and reliability of structural identification.
[0051] Figure 8 This is the carbon NMR spectrum of sitagliptin in CDCl3 solvent at 101 MHz; the horizontal axis represents the chemical shift δ (ppm), and the vertical axis represents the signal intensity. The chemical shift signals (δ: 170.57, 157.31, 155.01, 150.05, 147.51, 145.34, 121.74, 118.91, 105.47, 48.52, 43.23, 42.38, 41.58, 40.30, 39.07, 37.93) presented in the spectrum are... Figure 9 The carbon spectra complemented each other, further confirming the carbon skeleton structure of sitagliptin under different solvent environments, providing strong support for the accurate identification of the product structure.
[0052] Example 4: Verification of the cyclic catalytic stability of the immobilized enzyme column The procedures of Examples 2 and 3 were repeated to conduct 10 consecutive batches of scale-up production experiments. The same immobilized enzyme column was used for each batch. The substrate conversion rate, product yield, and purity of each batch were recorded during the experiments. The results are shown in Table 2 below: Table 2: Substrate conversion, product yield, and purity of 10 batches in scale-up production experiments
[0053] As shown in Table 2 above, after 10 batches of continuous cyclic catalysis using the immobilized enzyme column described in this invention, the substrate conversion rate remains above 94.8%, the product yield is stable above 80.8%, and the purity is maintained above 98.8%. This indicates that the immobilized enzyme column has excellent catalytic stability and recyclability, and can meet the needs of continuous industrial production.
[0054] VI. Explanation of Key Process Parameters In the synthesis of diketone substrates, the excess addition of N,N-diisopropylethylamine can effectively stabilize the Meldrum addition product, preventing its decomposition due to instability of free acid and improving the substrate synthesis yield; the stepwise addition of trifluoroacetic acid can precisely adjust the reaction pH and promote the formation of the target substrate.
[0055] The height-to-diameter ratio of the immobilized enzyme column is designed to be 4:3, which ensures sufficient contact between the reaction solution and the immobilized enzyme while reducing pressure loss within the column. The parameter setting of 0.6U of enzyme activity immobilized per 1g of epoxy resin achieves the optimal match between enzyme catalytic efficiency and carrier loading.
[0056] The catalytic reaction temperature was controlled at 45℃ and the pH was maintained at 9.5-10.0. Under these conditions, the transaminase (ATA-117) exhibited the highest catalytic activity and the enzyme structure could be effectively prevented from being deformed or destroyed by environmental factors. Optimization of substrate flow acceleration and circulating fluid flow rate could prevent enzyme inhibition caused by excessively high local substrate concentrations.
[0057] During product purification, the two-step extraction process of acidification-alkali adjustment can efficiently remove reaction impurities. In particular, by controlling the pH value before extraction, the extraction selectivity of sitagliptin can be significantly improved. Vacuum concentration and low-temperature drying conditions can prevent product degradation due to high temperature and ensure product quality stability.
[0058] The above embodiments merely illustrate implementation methods of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention.
Claims
1. A method for the enzymatic cyclic synthesis of sitagliptin phosphate, characterized in that, Using diketone substrates as reactants, an immobilized enzyme cyclic catalytic system is employed to replace the traditional hydrogenation chemical synthesis process. This immobilized enzyme cyclic catalytic system includes an immobilized enzyme column and optimized reaction conditions. The specific steps are as follows: Step (1): Synthesis of the diketone substrate: Starting with 2,2-dimethyl-1,3-dioxane-4,6-dione and 2,3,5-trifluorophenylacetic acid, the product was reacted in acetonitrile in the presence of N,N-diisopropylethylamine and a catalytic amount of 4-dimethylaminopyridine to generate the Meldrum addition product. The product was then reacted with triazole piperazine hydrochloride in a one-pot reaction system regulated by trifluoroacetic acid to synthesize the diketone substrate. Step (2): Preparation of immobilized enzyme column: The transaminase (ATA-117) prepared by fermentation was subjected to cell wall disruption, impurity removal, and ultrafiltration concentration to obtain enzyme concentrate. The concentrate was then immobilized by stirring with epoxy resin HFA001 at 30-40℃ for 12 hours, controlling the immobilization of 0.6U enzyme activity per 1g of epoxy resin. After filtration and washing, the concentrate was packed into a chromatography column with a height-to-diameter ratio of 4:
3. The volume of the immobilized enzyme packing was two-thirds of the column volume. The concentrate was then stored after being immersed in distilled water below 8℃ for later use. Step (3): Cyclic catalytic reaction: The diketone substrate is dissolved in dimethyl sulfoxide to form a substrate solution, which is then mixed with a catalytic solution containing pyridoxal phosphate and 3M isopropylamine hydrochloride. Cyclic catalysis is carried out in a fixed enzyme-carrying column. The reaction temperature is controlled at 45℃, the pH value is 9.5-10.0, the substrate solution flow rate is 4.5-5.0 L / h, the circulation liquid flow rate is 600-800 L / h, and the reaction is carried out for 10 hours until the substrate is completely converted. Step (4): Product separation and purification: The catalyst solution and the eluent are combined, and the product is purified by acid extraction, alkali extraction, organic phase washing and drying, vacuum concentration, crystallization and low temperature vacuum drying to obtain sitagliptin base.
2. The synthesis method according to claim 1, characterized in that, The specific conditions for the "one-pot" reaction described in step (1) are as follows: react at 55°C for 6 hours. During the reaction, triazole piperazine hydrochloride is added first, followed by the addition of trifluoroacetic acid. After the addition is complete, the reaction is kept warm. After the reaction is completed, 5% NaHCO3 aqueous solution is added dropwise in two batches. The mixture is cooled to 0-5°C and stirred to crystallize. After washing and drying, the diketone substrate is obtained.
3. The synthesis method according to claim 1, characterized in that, The fermentation preparation process of transaminase (ATA-117) in step (2) includes engineered bacteria culture, cell wall disruption, impurity removal and ultrafiltration concentration, and the enzyme activity of the enzyme concentrate after ultrafiltration concentration is not less than 8.3 g / L.
4. The synthesis method according to claim 1, characterized in that, The composition of the catalyst solution in step (3) is: 60g of pyridoxal phosphate, 1.5L of 3M isopropylamine hydrochloride (pH 9.5), 40L of dimethyl sulfoxide, and 30L of water. The concentration of the substrate solution is 4kg of diketone substrate dissolved in 16L of dimethyl sulfoxide.
5. The synthesis method according to claim 1, characterized in that, The cyclic catalytic process of the immobilized enzyme column in step (3) includes washing, catalytic solution circulation, substrate addition catalysis, top washing catalytic solution, elution, top washing eluent and storage steps. The immobilized enzyme column can continuously circulate catalysis for more than 10 batches, and the substrate conversion rate of each batch is not less than 95%.
6. The synthesis method according to claim 1, characterized in that, The specific conditions for separation and purification described in step (4) are as follows: (a) Acidification treatment: Adjust the pH of the combined solution to 2.0-3.0 with hydrochloric acid, add 5% sodium chloride, stir at 50°C for 30 min, and then cool to 10-30°C; (b) Acid extraction: Extract twice with 1 / 4 volume of ethyl acetate, and collect the aqueous phase; (c) Alkali-adjusted extraction: Adjust the pH of the aqueous phase to 11.0 with 12.0M NaOH, and extract three times with 1 / 3 volume of ethyl acetate, readjusting the pH to 11.0 before each extraction; (d) Organic phase treatment: washed with saturated NaCl solution, dried with anhydrous sodium sulfate, and filtered through a 0.45 μm organic filter membrane; (e) Vacuum concentration: Concentrate at 40±5℃ and a vacuum of -0.10 to -0.06 MPa until no liquid flows out; (f) Crystallization: Add isopropanol and heat to 55-65℃ to dissolve, add n-heptane dropwise, cool to 15-20℃ and stir to crystallize; (g) Drying: 40±5℃, vacuum degree -0.10~-0.06MPa, drying tray thickness <2.0cm, and collect the material after the drying loss is qualified.
7. The synthesis method according to claim 1, characterized in that, The method for preparing the immobilized enzyme packing is as follows: the transaminase concentrate is stirred and reacted with epoxy resin HFA001 at 30-40℃ for 12 hours, excess enzyme solution is removed by filtration, and the mixture is washed with pure water until there is no obvious foam. The immobilized enzyme packing is stored in purified water at 4-8℃, and the enzyme activity stability is maintained for more than 10 batches of catalytic cycles without decay.
